Fig. 2From: A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodineComparison of progression-free survival in the placebo arms of the DECISION and SELECT clinical trials. Source: Data provided during the NICE appraisal by Eisai Ltd. and Bayer HealthCareBack to article page